Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRV038
MIFTS: 57

Cervical Squamous Cell Carcinoma

Categories: Reproductive diseases, Rare diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cervical Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 38 12 59 55 15 73
Squamous Cell Carcinoma of the Cervix Uteri 12 59
Squamous Cell Carcinoma of Cervix 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3744
NCIt 50 C4028
SNOMED-CT 68 254886006
Orphanet 59 ORPHA213767
UMLS via Orphanet 74 C0279671
ICD10 via Orphanet 34 C53.0 C53.1 C53.8
UMLS 73 C0279671
Sources

Summaries for Cervical Squamous Cell Carcinoma

About this section
Disease Ontology : 12 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary : Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to cervical intraepithelial neoplasia and squamous cell carcinoma. An important gene associated with Cervical Squamous Cell Carcinoma is LOC105379013 (Uncharacterized LOC105379013
A 15-lncRNA based risk score was developed based on the Cox co-efficient of the individual lncRNAs. The prognostic value of this risk score was validated in the complete set and internal testing set. In summary, a 15-lncRNA expression signature (BAIAP2-AS1, RP11-203J24.8, LINC01133, RP1-7G5.6, RP11-147L13.15, SERHL, CTC-537E7.3, RP11-440L14.1, RP11-131N11.4, ILF3-AS1, RP11-80H18.4, RP11-1096G20.5, CTD-2192J16.26, RP11-621L6.3, and RP11-571M6.18) were identified and validated which can predict cervical cancer patient survival. The potential functions of this 15-lncRNA expression signature and individual lncRNAs as prognostic targets of cervical cancer were revealed by this study.
Dysfunction Pattern: Expression [low expression]), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are digestive/alimentary and neoplasm

Sources

Related Diseases for Cervical Squamous Cell Carcinoma

About this section

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
# Related Disease Score Top Affiliating Genes
1 cervical intraepithelial neoplasia 31.2 CDKN2A KRT8 MKI67
2 squamous cell carcinoma 30.9 CDH1 CDKN2A CTNNB1 MKI67 SERPINB3 TP53
3 endometrial adenocarcinoma 30.8 CDKN2A MKI67 TP53
4 cervical adenocarcinoma 30.8 CDKN2A RASSF1 TP53
5 adenocarcinoma 30.7 CDH1 CDKN2A CTNNB1 TP53
6 papilloma 30.1 CDKN2A KRT8 TP53 TP63
7 cervical cancer 28.5 CDKN2A CTNNB1 DAPK1 RASSF1 SERPINB3 TP53
8 microinvasive cervical squamous cell carcinoma 12.3
9 cervicitis 11.0
10 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
11 brain ependymoma 10.9 MKI67 TP53
12 cerebral convexity meningioma 10.8 CDH1 TP53
13 vulvar intraepithelial neoplasia 10.8 CDH1 TP53
14 ameloblastic carcinoma 10.8 CDKN2A MKI67 TP63
15 adult hepatocellular carcinoma 10.8 CTNNB1 TP53
16 keratinizing squamous cell carcinoma 10.8 CDKN2A TP53
17 tonsil cancer 10.8 CDKN2A SERPINB3
18 spitz nevus 10.7 CDKN2A MKI67 TP53
19 gallbladder adenoma 10.7 CDKN2A CTNNB1
20 large intestine adenocarcinoma 10.7 CDH1 CTNNB1
21 oral leukoplakia 10.7 CDKN2A MKI67 TP53
22 anal squamous cell carcinoma 10.7 CDKN2A RASSF1 TP53
23 actinic keratosis 10.7 CDKN2A TP53 TP63
24 pre-malignant neoplasm 10.7 CDH1 CDKN2A TP53
25 in situ carcinoma 10.7 CDH1 CDKN2A TP53
26 hidradenocarcinoma 10.7 MKI67 TP53 TP63
27 calcifying epithelial odontogenic tumor 10.7 KRT8 TP53
28 benign breast phyllodes tumor 10.7 MKI67 TP63
29 pharynx cancer 10.7 CDH1 CDKN2A TP53
30 tongue cancer 10.7 CDH1 CDKN2A TP53
31 female reproductive endometrioid cancer 10.7 CTNNB1 TP53
32 vulva squamous cell carcinoma 10.7 CDKN2A SERPINB3 TP53
33 epstein-barr virus-associated gastric carcinoma 10.7 CDH1 CDKN2A CTNNB1
34 endometrial mucinous adenocarcinoma 10.6 CDKN2A MKI67
35 polymorphous low-grade adenocarcinoma 10.6 CTNNB1 MKI67 TP63
36 goblet cell carcinoid 10.6 CDH1 CTNNB1
37 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 CTNNB1 TP53 TP63
38 oral cancer 10.6 CDH1 CDKN2A TP53
39 chordoma 10.6 CDH1 CDKN2A TP53
40 endocrine gland cancer 10.6 CDH1 CDKN2A TP53
41 vulva cancer 10.6 CDKN2A SERPINB3 TP53
42 oropharynx cancer 10.6 CDKN2A TP53 TYMP
43 signet ring cell adenocarcinoma 10.6 CDH1 CTNNB1 TP53
44 embryonal sarcoma 10.6 CTNNB1 MKI67 TP53
45 bladder carcinoma in situ 10.6 CDKN2A TP53
46 intestinal benign neoplasm 10.6 CDH1 CTNNB1 TP53
47 cell type benign neoplasm 10.6 CDKN2A CTNNB1 TP53
48 pancreatic ductal carcinoma 10.6 CDKN2A TP53 TYMP
49 basaloid squamous cell carcinoma 10.6 CDKN2A KRT8 TP53
50 anaplastic thyroid cancer 10.6 CDH1 CTNNB1 TP53

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

About this section

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CDH1 CDKN2A CTNNB1 KRT8 RASSF1 TP53
2 neoplasm MP:0002006 9.43 CTNNB1 RASSF1 TP53 TP63 CDH1 CDKN2A
3 no phenotypic analysis MP:0003012 9.17 CDH1 CDKN2A CTNNB1 MKI67 OSMR TP53
Sources

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

About this section

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Vinblastine Approved Phase 3 865-21-4 13342 241903
10
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
11
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
12
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
18
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
19 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
20 Antibodies Phase 3,Phase 2,Phase 1
21 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Immunoglobulins Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antiviral Agents Phase 3,Phase 2,Phase 1
27 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
30 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
31 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
32 Immunoglobulin G Phase 3,Phase 2,Phase 1
33 Mitogens Phase 3,Phase 2,Phase 1
34 Antimetabolites Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
37 Alkylating Agents Phase 3,Phase 2
38 Anti-Bacterial Agents Phase 3,Phase 2,Early Phase 1
39 Antibiotics, Antitubercular Phase 3,Phase 2,Early Phase 1
40 Antineoplastic Agents, Alkylating Phase 3,Phase 2
41 Antirheumatic Agents Phase 3,Phase 1,Phase 2
42 Dermatologic Agents Phase 3,Phase 2
43 Folic Acid Antagonists Phase 3,Phase 2
44
Isophosphamide mustard Phase 3 0
45 Mitomycins Phase 3,Phase 2
46 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
47 Vitamin B Complex Phase 3,Phase 2
48 Folate Nutraceutical Phase 3,Phase 2
49 Vitamin B9 Nutraceutical Phase 3,Phase 2
50
Letrozole Approved, Investigational Phase 2 112809-51-5 3902

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
4 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
5 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
6 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
7 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
8 A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix Recruiting NCT02765919 Phase 3
9 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
10 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
11 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
12 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
13 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
14 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
15 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
16 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
17 A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix Unknown status NCT02482740 Phase 2 Letrozole;tamoxifen
18 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
19 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
20 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
21 Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
22 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed NCT00025233 Phase 2
23 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer Completed NCT00002813 Phase 2 cisplatin;vinorelbine tartrate
24 Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00041093 Phase 2 Docetaxel
25 Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer Completed NCT00005837 Phase 2 oxaliplatin
26 SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00026260 Phase 2 semaxanib
27 Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00016926 Phase 2 capecitabine
28 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00499031 Phase 2
29 Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application Completed NCT01639625 Phase 2 CIGB300
30 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed NCT00087126 Phase 2 topotecan hydrochloride
31 Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Completed NCT02562729 Phase 2
32 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
33 Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005999 Phase 2 arsenic trioxide
34 Docetaxel in Treating Patients With Advanced Cancer of the Cervix Completed NCT00003445 Phase 2 docetaxel
35 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
36 DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix Completed NCT00004866 Phase 2 exatecan mesylate
37 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
38 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
39 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
40 Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00691301 Phase 2 cisplatin;pemetrexed disodium
41 Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix Completed NCT00087113 Phase 2 pemetrexed disodium
42 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
43 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
44 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
45 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
46 Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
47 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed NCT00559377 Phase 2
48 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
49 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
50 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Sources

Genetic Tests for Cervical Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Cervical Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

41
Cervix, Uterus, Lymph Node, Testes, Bone, T Cells, Endothelial
Sources

Publications for Cervical Squamous Cell Carcinoma

About this section

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 351)
# Title Authors Year
1
Identification of a microRNA signature associated with survivability in cervical squamous cell carcinoma. ( 29513728 )
2018
2
Superficially invasive cervical squamous cell carcinoma metastatic to ovarian endometriotic cyst wall, a case report and brief review of the literature. ( 29848369 )
2018
3
The correlation analysis of miRNAs and target genes in metastasis of cervical squamous cell carcinoma. ( 29343084 )
2018
4
EZH2, Endothelin-1, and CD34 as Biomarkers of Aggressive Cervical Squamous Cell Carcinoma: An Immunohistochemical Study. ( 29630085 )
2018
5
A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma. ( 29525275 )
2018
6
LncRNA PVT1 promotes the growth of HPV positive and negative cervical squamous cell carcinoma by inhibiting TGF-I^1. ( 29760583 )
2018
7
Which Patients With Cervical Squamous Cell Carcinoma Might Benefit From Neoadjuvant Chemotherapy? ( 29668367 )
2018
8
Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1I+-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines. ( 29958416 )
2018
9
Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma. ( 29154871 )
2018
10
FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting I^-catenin through mRNA demethylation. ( 29315835 )
2018
11
Differentiated cervical intraepithelial neoplasia-associated invasive cervical squamous cell carcinoma as a source of major cytopathological and surgical pathological discrepancy in Papanicolaou smear screening tests. ( 29575422 )
2018
12
MiRNA373 induces cervical squamous cell carcinoma SiHa cell apoptosis. ( 29125482 )
2018
13
Towards developing a meaningful grading system for cervical squamous cell carcinoma. ( 29665326 )
2018
14
Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study. ( 29445289 )
2018
15
E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma. ( 29400024 )
2018
16
MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas. ( 28802022 )
2018
17
The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis. ( 29606483 )
2018
18
Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance. ( 29780775 )
2018
19
Comprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian Women. ( 28717764 )
2017
20
Early vulvar and umbilical incisional scar recurrence of cervical squamous cell carcinoma: Earlier than usually expected. ( 28913152 )
2017
21
Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis. ( 28914639 )
2017
22
Characterization of the microRNA profile in early-stage cervical squamous cell carcinoma by next-generation sequencing. ( 28098890 )
2017
23
Chondrosarcoma-like metastasis from a poorly differentiated uterine cervical squamous cell carcinoma. A unique morphology and diagnostic pitfall in cytology. ( 28411397 )
2017
24
Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma. ( 29101499 )
2017
25
Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. ( 28526810 )
2017
26
Association of Casp3 microRNA Target Site (1049216) SNP With the Risk and Progress of Cervical Squamous Cell Carcinoma. ( 28114230 )
2017
27
Sulfiredoxin may promote metastasis and invasion of cervical squamous cell carcinoma by epithelial-mesenchymal transition. ( 28351308 )
2017
28
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. ( 28833798 )
2017
29
Down-regulation of IFITM1 and its growth inhibitory role in cervical squamous cell carcinoma. ( 29051711 )
2017
30
Associations between intratumoral and peritumoral M2 macrophage counts and cervical squamous cell carcinoma invasion patterns. ( 28884821 )
2017
31
[Highly expressed sulfiredoxin and I^-catenin are associated with malignancy of cervical squamous cell carcinoma]. ( 28274319 )
2017
32
Serum MicroRNAs Related with Chemoradiotherapy Resistance in Advanced-Stage Cervical Squamous Cell Carcinoma. ( 28432899 )
2017
33
SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma. ( 29109451 )
2017
34
Corrigendum to &amp;quot;Expression of HIF-2<i>I+</i>and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance&amp;quot;. ( 29124066 )
2017
35
Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis. ( 28404933 )
2017
36
Pre-microRNA Gene Polymorphisms and Risk of Cervical Squamous Cell Carcinoma. ( 29207732 )
2017
37
Amplification and up-regulation of MIR30D was associated with disease progression of cervical squamous cell carcinomas. ( 28356144 )
2017
38
Expression of Estrogen and Progesterone Receptor in Tumor Stroma Predicts Favorable Prognosis of Cervical Squamous Cell Carcinoma. ( 28472813 )
2017
39
Suppressor of fused (Sufu) promotes epithelial-mesenchymal transition (EMT) in cervical squamous cell carcinoma. ( 29371981 )
2017
40
Radiation therapy versus surgery for patients with cervical squamous cell carcinoma who have undergone neoadjuvant chemotherapy revisited. ( 28929314 )
2017
41
Establishment and analysis of the prediction model for cervical squamous cell carcinoma. ( 29228452 )
2017
42
Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. ( 29022484 )
2017
43
Short interfering RNA targeting Net1 reduces the angiogenesis and tumor growth of in vivo cervical squamous cell carcinoma through VEGF down-regulation. ( 28511963 )
2017
44
Fatty acid binding protein 4 promotes epithelial-mesenchymal transition in cervical squamous cell carcinoma through AKT/GSK3I^/Snail signaling pathway. ( 28893569 )
2017
45
Proteomic identification of potential biomarkers for cervical squamous cell carcinoma and human papillomavirus infection. ( 28443473 )
2017
46
Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study. ( 27131759 )
2016
47
A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma. ( 27145272 )
2016
48
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy. ( 27400321 )
2016
49
Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. ( 27779103 )
2016
50
High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. ( 27941992 )
2016
Sources

Variations for Cervical Squamous Cell Carcinoma

About this section

Cosmic variations for Cervical Squamous Cell Carcinoma:

9
(show top 50) (show all 175)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6917051 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 12
2 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 12
3 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 12
4 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 12
5 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 12
6 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 17:7673814-7673814 12
7 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 12
8 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 12
9 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 12
10 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 12
11 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 12
12 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 17:7675185-7675185 12
13 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 17:7673745-7673745 12
14 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 12
15 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 17:7673802-7673802 12
16 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 17:7673790-7673790 12
17 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 17:7676068-7676068 12
18 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 12
19 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 17:7674237-7674237 12
20 COSM6917055 TOP1 cervix,NS,carcinoma,squamous cell carcinoma c.1897C>T p.Q633* 20:41118243-41118243 12
21 COSM6933657 TGFBR2 cervix,NS,carcinoma,squamous cell carcinoma c.931G>T p.E311* 3:30672114-30672114 12
22 COSM6918339 TET2 cervix,NS,carcinoma,squamous cell carcinoma c.2659G>A p.E887K 4:105236601-105236601 12
23 COSM6906292 TENT5C cervix,NS,carcinoma,squamous cell carcinoma c.722G>T p.G241V 1:117623590-117623590 12
24 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 19:1220630-1220630 12
25 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 19:1218446-1218446 12
26 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 19:1220505-1220505 12
27 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 19:1207082-1207082 12
28 COSM6977087 SPOP cervix,NS,carcinoma,squamous cell carcinoma c.962C>T p.A321V 17:49601883-49601883 12
29 COSM421102 ROS1 cervix,NS,carcinoma,squamous cell carcinoma c.1682C>T p.P561L 6:117389427-117389427 12
30 COSM6977085 RB1 cervix,NS,carcinoma,squamous cell carcinoma c.1630A>T p.R544* 13:48381378-48381378 12
31 COSM6910533 RAD54L cervix,NS,carcinoma,squamous cell carcinoma c.1900C>T p.R634C 1:46277847-46277847 12
32 COSM6977079 RAD50 cervix,NS,carcinoma,squamous cell carcinoma c.432G>C p.E144D 5:132587654-132587654 12
33 COSM6977082 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1702C>T p.Q568* 8:116848948-116848948 12
34 COSM6977083 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1681C>T p.Q561* 8:116848969-116848969 12
35 COSM6975050 PTPRS cervix,NS,carcinoma,squamous cell carcinoma c.5630C>G p.S1877C 19:5208249-5208249 12
36 COSM6917045 PTPRD cervix,NS,carcinoma,squamous cell carcinoma c.1693G>A p.E565K 9:8504390-8504390 12
37 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 10:87952142-87952142 12
38 COSM5945791 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.65A>G p.D22G 10:87864534-87864534 12
39 COSM4822061 POLE cervix,NS,carcinoma,squamous cell carcinoma c.865G>A p.E289K 12:132676590-132676590 12
40 COSM6937072 PIK3R1 cervix,NS,carcinoma,squamous cell carcinoma c.1859A>G p.D620G 5:68296215-68296215 12
41 COSM43062 PIK3CG cervix,NS,carcinoma,squamous cell carcinoma c.53G>A p.R18Q 7:106867614-106867614 12
42 COSM5878662 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1579G>A p.D527N 3:179218249-179218249 12
43 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 3:179234286-179234286 12
44 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 12
45 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 3:179218294-179218294 12
46 COSM12584 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1357G>A p.E453K 3:179210291-179210291 12
47 COSM27134 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3130A>G p.N1044D 3:179234287-179234287 12
48 COSM775 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 3:179234297-179234297 12
49 COSM17442 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>C p.E542Q 3:179218294-179218294 12
50 COSM29313 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>A p.M1043I 3:179234286-179234286 12

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

7 (show all 38)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain POLS Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJA5 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain KIAA0947 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCH-VI Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain OSRF Cervical squamous cell carcinoma
Sources

Expression for Cervical Squamous Cell Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1, type II Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T-cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4, type II Uterus - 4.45 0.000
6 SPRR3 small proline-rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin-dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine-rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine-rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor, Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C-I Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI Fanconi anemia, complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin, alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13, type I Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1, regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor, type II Uterus - 3.14 0.000
28 CFD complement factor D (adipsin) Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, polyU-specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.
Sources

Pathways for Cervical Squamous Cell Carcinoma

About this section

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 37
12.35 CDH1 CDKN2A CTNNB1 DAPK1 RASSF1 TP53
2
MicroRNAs in cancer 37
12.18 CDKN2A RASSF1 TP53 TP63
3
DNA Damage 4
12.14 CDKN2A MKI67 TP53 TP63
4
DNA Damage Response (only ATM dependent) 1
11.69 CDKN2A CTNNB1 TP53
5
Glioblastoma Multiforme 64
11.65 CDKN2A CTNNB1 TP53
6
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.3 CTNNB1 KRT8 MKI67
7
Bladder cancer 37 1
10.96 CDH1 CDKN2A DAPK1 RASSF1 TP53 TYMP
8
TP53 Network 1
Show member pathways
 10.47 CDKN2A TP53 TP63
9
RHO GTPases activate IQGAPs 66
10.44 CDH1 CTNNB1
Sources

GO Terms for Cervical Squamous Cell Carcinoma

About this section

Cellular components related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.85 CDH1 CDKN2A CTNNB1 TP53 TP63
2 regulation of apoptotic process GO:0042981 9.78 CTNNB1 DAPK1 TP53 TP63
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 TP53 TP63
4 regulation of myelination GO:0031641 9.4 CTNNB1 TYMP
5 replicative senescence GO:0090399 9.37 CDKN2A TP53
6 Ras protein signal transduction GO:0007265 9.33 CDKN2A RASSF1 TP53
7 entry of bacterium into host cell GO:0035635 9.32 CDH1 CTNNB1
8 mitotic G1 DNA damage checkpoint GO:0031571 9.26 TP53 TP63
9 cranial skeletal system development GO:1904888 8.96 CTNNB1 TP63
10 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNB1

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53
Sources

Sources for Cervical Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....